{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:02:55Z","timestamp":1793430175822,"version":"4.5.0"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41571-019-0203-7","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T06:03:37Z","timestamp":1553580217000},"page":"425-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":654,"title":["Navigating metabolic pathways to enhance antitumour immunity and immunotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Xiaoyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-3737","authenticated-orcid":false,"given":"Stanley Ching-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Maria","family":"Fendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-3774","authenticated-orcid":false,"given":"Ping-Chih","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"203_CR1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351 (2015).","journal-title":"Nat. Cell Biol."},{"key":"203_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/boc.201500015","volume":"107","author":"D Lorendeau","year":"2015","unstructured":"Lorendeau, D., Christen, S., Rinaldi, G. & Fendt, S.-M. Metabolic control of signaling pathways and metabolic auto-regulation. Biol. Cell 107, 251\u2013272 (2015).","journal-title":"Biol. Cell"},{"key":"203_CR3","volume":"10","author":"G Rinaldi","year":"2018","unstructured":"Rinaldi, G., Rossi, M. & Fendt, S.-M. Metabolic interactions in cancer: cellular metabolism at the interface between the microenvironment, the cancer cell phenotype and the epigenetic landscape. Wiley Interdiscip. Rev. Syst. Biol. Med. 10, e1397 (2018).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"203_CR4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619\u2013634 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"203_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2017.00289","volume":"8","author":"X Geeraerts","year":"2017","unstructured":"Geeraerts, X., Bolli, E., Fendt, S.-M. & Van Ginderachter, J. A. Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. Front. Immunol. 8, 289 (2017).","journal-title":"Front. Immunol."},{"key":"203_CR6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/nrc.2016.85","volume":"16","author":"LB Sullivan","year":"2016","unstructured":"Sullivan, L. B., Gui, D. Y. & Heiden, M. G. V. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat. Rev. Cancer 16, 680 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"203_CR7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2016.04.025","volume":"100","author":"M Sciacovelli","year":"2016","unstructured":"Sciacovelli, M. & Frezza, C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radic. Biol. Med. 100, 175\u2013181 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"203_CR8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.tibs.2016.02.003","volume":"41","author":"R Haas","year":"2016","unstructured":"Haas, R. et al. Intermediates of metabolism: from bystanders to signalling molecules. Trends Biochem. Sci. 41, 460\u2013471 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"203_CR9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2018.07.030","volume":"174","author":"MP Murphy","year":"2018","unstructured":"Murphy, M. P. & O\u2019Neill, L. A. J. Krebs cycle reimagined: the emerging roles of succinate and itaconate as signal transducers. Cell 174, 780\u2013784 (2018).","journal-title":"Cell"},{"key":"203_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.011008.145616","volume":"49","author":"T Shimizu","year":"2009","unstructured":"Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49, 123\u2013150 (2009).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"203_CR11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","volume":"15","author":"EA Dennis","year":"2015","unstructured":"Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol. 15, 511\u2013523 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"203_CR12","first-page":"76","volume":"1870","author":"J Bi","year":"2018","unstructured":"Bi, J., Wu, S., Zhang, W. & Mischel, P. S. Targeting cancer\u2019s metabolic co-dependencies: a landscape shaped by genotype and tissue context. Biochim. Biophys. Acta 1870, 76\u201387 (2018).","journal-title":"Biochim. Biophys. Acta"},{"key":"203_CR13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/164_2015_10","volume":"233","author":"I Elia","year":"2016","unstructured":"Elia, I., Schmieder, R., Christen, S. & Fendt, S.-M. Organ-specific cancer metabolism and its potential for therapy. Handb. Exp. Pharmacol. 233, 321\u2013353 (2016).","journal-title":"Handb. Exp. Pharmacol."},{"key":"203_CR14","doi-asserted-by":"crossref","first-page":"S1284","DOI":"10.21037\/tcr.2016.11.53","volume":"5","author":"I Elia","year":"2016","unstructured":"Elia, I. & Fendt, S.-M. In vivo cancer metabolism is defined by the nutrient microenvironment. Transl Cancer Res. 5, S1284\u2013S1287 (2016).","journal-title":"Transl Cancer Res."},{"key":"203_CR15","doi-asserted-by":"crossref","first-page":"dmm035758","DOI":"10.1242\/dmm.035758","volume":"11","author":"A Muir","year":"2018","unstructured":"Muir, A., Danai, L. V. & Vander Heiden, M. G. Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Dis. Model. Mech. 11, dmm035758 (2018).","journal-title":"Dis. Model. Mech."},{"key":"203_CR16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.tcb.2018.04.002","volume":"28","author":"I Elia","year":"2018","unstructured":"Elia, I., Doglioni, G. & Fendt, S.-M. Metabolic hallmarks of metastasis formation. Trends Cell Biol. 28, 673\u2013684 (2018).","journal-title":"Trends Cell Biol."},{"key":"203_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coisb.2017.12.006","volume":"8","author":"SY Lunt","year":"2018","unstructured":"Lunt, S. Y. & Fendt, S.-M. Metabolism \u2014 a cornerstone of cancer initiation, progression, immune evasion and treatment response. Curr. Opin. Syst. Biol. 8, 67\u201372 (2018).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"203_CR18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MGV Heiden","year":"2017","unstructured":"Heiden, M. G. V. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657\u2013669 (2017).","journal-title":"Cell"},{"key":"203_CR19","volume":"10","author":"ST Teoh","year":"2018","unstructured":"Teoh, S. T. & Lunt, S. Y. Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. Wiley Interdiscip. Rev. Syst. Biol. Med. 10, e1406 (2018).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"203_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science 123, 309 (1956).","journal-title":"Science"},{"key":"203_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/iub.573","volume":"64","author":"AP Halestrap","year":"2012","unstructured":"Halestrap, A. P. The monocarboxylate transporter family \u2014 structure and functional characterization. IUBMB Life 64, 1\u20139 (2012).","journal-title":"IUBMB Life"},{"key":"203_CR22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"203_CR23","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"PC Ho","year":"2015","unstructured":"Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217\u20131228 (2015).","journal-title":"Cell"},{"key":"203_CR24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","volume":"28","author":"W Li","year":"2018","unstructured":"Li, W. et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 28, 87\u2013103 (2018).","journal-title":"Cell Metab."},{"key":"203_CR25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.0902584","volume":"184","author":"K Dietl","year":"2010","unstructured":"Dietl, K. et al. Lactic acid and acidification inhibit TNF\u00a0secretion and glycolysis of human monocytes. J.\u00a0Immunol. 184, 1200\u20131209 (2010).","journal-title":"J. Immunol."},{"key":"203_CR26","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013\u20132021 (2006).","journal-title":"Blood"},{"key":"203_CR27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature 496, 238\u2013242 (2013).","journal-title":"Nature"},{"key":"203_CR28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559\u2013563 (2014).","journal-title":"Nature"},{"key":"203_CR29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","volume":"191","author":"Z Husain","year":"2013","unstructured":"Husain, Z., Huang, Y., Seth, P. & Sukhatme, V. P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191, 1486\u20131495 (2013).","journal-title":"J. Immunol."},{"key":"203_CR30","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.4049\/jimmunol.180.11.7175","volume":"180","author":"H Shime","year":"2008","unstructured":"Shime, H. et al. Tumor-secreted lactic acid promotes IL-23\/IL-17 proinflammatory pathway. J. Immunol. 180, 7175\u20137183 (2008).","journal-title":"J. Immunol."},{"key":"203_CR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature24057","volume":"551","author":"S Hui","year":"2017","unstructured":"Hui, S. et al. Glucose feeds the TCA cycle via circulating lactate. Nature 551, 115 (2017).","journal-title":"Nature"},{"key":"203_CR32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert, B. et al. Lactate metabolism in human lung tumors. Cell 171, 358\u2013371 (2017).","journal-title":"Cell"},{"key":"203_CR33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","volume":"27","author":"T Cascone","year":"2018","unstructured":"Cascone, T. et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 27, 977\u2013987 (2018).","journal-title":"Cell Metab."},{"key":"203_CR34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657\u2013671 (2016).","journal-title":"Cell Metab."},{"key":"203_CR35","doi-asserted-by":"crossref","first-page":"14083","DOI":"10.1007\/s13277-016-5228-2","volume":"37","author":"R Liu","year":"2016","unstructured":"Liu, R. et al. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU\/L. Tumor Biol. 37, 14083\u201314088 (2016).","journal-title":"Tumor Biol."},{"key":"203_CR36","first-page":"916","volume":"60","author":"S Walenta","year":"2000","unstructured":"Walenta, S. et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60, 916\u2013921 (2000).","journal-title":"Cancer Res."},{"key":"203_CR37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230\u2013233 (2008).","journal-title":"Nature"},{"key":"203_CR38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/cncr.28501","volume":"120","author":"SE Elf","year":"2014","unstructured":"Elf, S. E. & Chen, J. Targeting glucose metabolism in patients with cancer. Cancer 120, 774\u2013780 (2014).","journal-title":"Cancer"},{"key":"203_CR39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.chembiol.2012.07.021","volume":"19","author":"C Kung","year":"2012","unstructured":"Kung, C. et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19, 1187\u20131198 (2012).","journal-title":"Chem. Biol."},{"key":"203_CR40","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fimmu.2017.01300","volume":"8","author":"EM Palsson-McDermott","year":"2017","unstructured":"Palsson-McDermott, E. M. et al. Pyruvate kinase M2 is required for the expression of the immune checkpoint PD-L1 in immune cells and tumors. Front. Immunol. 8, 1300 (2017).","journal-title":"Front. Immunol."},{"key":"203_CR41","volume":"9","author":"F-L Li","year":"2018","unstructured":"Li, F.-L. et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat. Commun. 9, 508 (2018).","journal-title":"Nat. Commun."},{"key":"203_CR42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13046-016-0481-1","volume":"36","author":"H-M Li","year":"2017","unstructured":"Li, H.-M. et al. Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma. J. Exp. Clin. Cancer Res. 36, 7 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"203_CR43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e14548","volume":"34","author":"JA Chesney","year":"2016","unstructured":"Chesney, J. A., Telang, S., Yaddanapudi, K. & Grewal, J. S. Targeting 6-phosphofructo-2-kinase (PFKFB3) as an immunotherapeutic strategy. J. Clin. Oncol. 34, e14548 (2016).","journal-title":"J. Clin. Oncol."},{"key":"203_CR44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/icb.2009.77","volume":"88","author":"M Yang","year":"2010","unstructured":"Yang, M. et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol. Cell Biol. 88, 165\u2013171 (2010).","journal-title":"Immunol. Cell Biol."},{"key":"203_CR45","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/jm980334n","volume":"41","author":"LM Deck","year":"1998","unstructured":"Deck, L. M. et al. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite plasmodium falciparum. J. Med. Chem. 41, 3879\u20133887 (1998).","journal-title":"J. Med. Chem."},{"key":"203_CR46","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin.\u00a0Cancer Res. 22, 5487\u20135496 (2016).","journal-title":"Clin. Cancer Res."},{"key":"203_CR47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nchembio744","volume":"1","author":"CM Murray","year":"2005","unstructured":"Murray, C. M. et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol. 1, 371\u2013376 (2005).","journal-title":"Nat. Chem. Biol."},{"key":"203_CR48","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas, S. et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76, 1381\u20131390 (2016).","journal-title":"Cancer Res."},{"key":"203_CR49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/15384101.2015.1120930","volume":"15","author":"J P\u00e9rez-Escuredo","year":"2016","unstructured":"P\u00e9rez-Escuredo, J. et al. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell\u00a0Cycle 15, 72\u201383 (2016).","journal-title":"Cell Cycle"},{"key":"203_CR50","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4161\/cbt.12.12.18671","volume":"12","author":"Y-H Ko","year":"2011","unstructured":"Ko, Y.-H. et al. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells. Cancer Biol. Ther. 12, 1085\u20131097 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"203_CR51","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","volume":"125","author":"Y Xiang","year":"2015","unstructured":"Xiang, Y. et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293\u20132306 (2015).","journal-title":"J. Clin. Invest."},{"key":"203_CR52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","volume":"18","author":"JB Wang","year":"2010","unstructured":"Wang, J. B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207\u2013219 (2010).","journal-title":"Cancer Cell"},{"key":"203_CR53","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890\u2013901 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"203_CR54","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chembiol.2014.08.007","volume":"21","author":"B DeLaBarre","year":"2014","unstructured":"DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S. & Dang, L. Action at a distance: allostery and the development of drugs to target cancer cell metabolism. Chem. Biol. 21, 1143\u20131161 (2014).","journal-title":"Chem. Biol."},{"key":"203_CR55","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.0903586","volume":"185","author":"EL Carr","year":"2010","unstructured":"Carr, E. L. et al. Glutamine uptake and metabolism are coordinately regulated by ERK\/MAPK during T lymphocyte activation. J. Immunol. 185, 1037\u20131044 (2010).","journal-title":"J. Immunol."},{"key":"203_CR56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1042\/bj2420631","volume":"242","author":"P Newsholme","year":"1987","unstructured":"Newsholme, P., Gordon, S. & Newsholme, E. A. Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. Biochem. J. 242, 631\u2013636 (1987).","journal-title":"Biochem. J."},{"key":"203_CR57","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ni.3796","volume":"18","author":"P-S Liu","year":"2017","unstructured":"Liu, P.-S. et al. \u03b1-Ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat. Immunol. 18, 985 (2017).","journal-title":"Nat. Immunol."},{"key":"203_CR58","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1111\/cas.13827","volume":"109","author":"S Nabe","year":"2018","unstructured":"Nabe, S. et al. Reinforce the antitumor activity of CD8+ T cells via glutamine restriction. Cancer Sci. 109, 3737\u20133750 (2018).","journal-title":"Cancer Sci."},{"key":"203_CR59","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.cell.2018.10.001","volume":"175","author":"MO Johnson","year":"2018","unstructured":"Johnson, M. O. et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell 175, 1780\u20131795 (2018).","journal-title":"Cell"},{"issue":"15_suppl","key":"203_CR60","doi-asserted-by":"crossref","first-page":"TPS4601","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4601","volume":"36","author":"Nizar M. Tannir","year":"2018","unstructured":"Tannir, N. M. et al. CANTATA: a randomized phase 2 study of CB-839 in combination with cabozantinib versus placebo with cabozantinib in patients with advanced\/metastatic renal cell carcinoma. J. Clin. Oncol. 36, TPS4601 (2018).","journal-title":"Journal of Clinical Oncology"},{"key":"203_CR61","doi-asserted-by":"crossref","first-page":"ra97","DOI":"10.1126\/scisignal.aab2610","volume":"8","author":"D Klysz","year":"2015","unstructured":"Klysz, D. et al. Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci. Signal. 8, ra97 (2015).","journal-title":"Sci. Signal."},{"issue":"Suppl","key":"203_CR62","doi-asserted-by":"crossref","first-page":"47.24","DOI":"10.4049\/jimmunol.200.Supp.47.24","volume":"200","author":"A Shanker","year":"2018","unstructured":"Shanker, A., de Aquino, M. T. P., Hodo, T. & Uzhachenko, R. Glutamate receptors provide costimulatory signals to improve T cell immune response. J. Immunol. 200 (Suppl), 47.24 (2018).","journal-title":"J. Immunol."},{"key":"203_CR63","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/mol.67.3.856","volume":"67","author":"C Poulopoulou","year":"2005","unstructured":"Poulopoulou, C. et al. Modulation of voltage-gated potassium channels in human T lymphocytes by extracellular glutamate. Mol. Pharmacol. 67, 856\u2013867 (2005).","journal-title":"Mol. Pharmacol."},{"key":"203_CR64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2017.05.004","volume":"35","author":"U Grohmann","year":"2017","unstructured":"Grohmann, U. et al. Amino-acid sensing and degrading pathways in immune regulation. Cytokine Growth Factor Rev. 35, 37\u201345 (2017).","journal-title":"Cytokine Growth Factor Rev."},{"key":"203_CR65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri.2016.80","volume":"16","author":"DE Speiser","year":"2016","unstructured":"Speiser, D. E., Ho, P. C. & Verdeil, G. Regulatory circuits of T cell function in cancer. Nat. Rev. Immunol. 16, 599\u2013611 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"203_CR66","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/15384047.2016.1276136","volume":"18","author":"X He","year":"2017","unstructured":"He, X., Lin, H., Yuan, L. & Li, B. Combination therapy with L-arginine and alpha-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice. Cancer Biol. Ther. 18, 94\u2013100 (2017).","journal-title":"Cancer Biol. Ther."},{"key":"203_CR67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R. et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829\u2013842 (2016).","journal-title":"Cell"},{"key":"203_CR68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda, S. M. et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J.\u00a0Immunother. Cancer 5, 101 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"203_CR69","doi-asserted-by":"crossref","first-page":"ra31","DOI":"10.1126\/scisignal.2004761","volume":"7","author":"F Qiu","year":"2014","unstructured":"Qiu, F. et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci. Signal. 7, ra31 (2014).","journal-title":"Sci. Signal."},{"key":"203_CR70","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bjc.2011.524","volume":"106","author":"MP Kelly","year":"2011","unstructured":"Kelly, M. P. et al. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br. J. Cancer 106, 324\u2013332 (2011).","journal-title":"Br. J. Cancer"},{"key":"203_CR71","volume":"7","author":"H-J Tsai","year":"2017","unstructured":"Tsai, H.-J. et al. A phase II study of arginine deiminase (ADI-PEG20) in relapsed\/refractory or poor-risk acute myeloid leukemia patients. Sci. Rep. 7, 11253 (2017).","journal-title":"Sci. Rep."},{"key":"203_CR72","doi-asserted-by":"crossref","first-page":"58948","DOI":"10.18632\/oncotarget.19564","volume":"8","author":"E Brin","year":"2017","unstructured":"Brin, E. et al. PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget 8, 58948\u201358963 (2017).","journal-title":"Oncotarget"},{"key":"203_CR73","volume":"6","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci. Rep. 6, 21319 (2016).","journal-title":"Sci. Rep."},{"key":"203_CR74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines3030703","volume":"3","author":"JC Mbongue","year":"2015","unstructured":"Mbongue, J. C. et al. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines 3, 703\u2013729 (2015).","journal-title":"Vaccines"},{"key":"203_CR75","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","volume":"22","author":"DH Munn","year":"2005","unstructured":"Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633\u2013642 (2005).","journal-title":"Immunity"},{"key":"203_CR76","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4161\/cbt.8.14.8882","volume":"8","author":"R Li","year":"2009","unstructured":"Li, R. et al. IDO inhibits T-cell function through suppressing Vav1 expression and activation. Cancer Biol. Ther. 8, 1402\u20131408 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"203_CR77","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-018-0701-2","volume":"563","author":"SJF Cronin","year":"2018","unstructured":"Cronin, S. J. F. et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature 563, 564\u2013568 (2018).","journal-title":"Nature"},{"key":"203_CR78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41590-018-0255-3","volume":"20","author":"PS Minhas","year":"2019","unstructured":"Minhas, P. S. et al. Macrophage de novo NAD(+) synthesis specifies immune function in aging and inflammation. Nat. Immunol. 20, 50\u201363 (2019).","journal-title":"Nat. Immunol."},{"key":"203_CR79","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ijc.27710","volume":"132","author":"X Zheng","year":"2013","unstructured":"Zheng, X. et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int. J. Cancer 132, 967\u2013977 (2013).","journal-title":"Int. J. Cancer"},{"key":"203_CR80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/1078-0432.CCR-08-1988","volume":"15","author":"M-C Yen","year":"2009","unstructured":"Yen, M.-C. et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin.\u00a0Cancer Res. 15, 641\u2013649 (2009).","journal-title":"Clin. Cancer Res."},{"key":"203_CR81","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/j.1349-7006.2011.02094.x","volume":"102","author":"T-T Huang","year":"2011","unstructured":"Huang, T.-T. et al. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci. 102, 2214\u20132220 (2011).","journal-title":"Cancer Sci."},{"key":"203_CR82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/PPO.0b013e3181eb3343","volume":"16","author":"H Soliman","year":"2010","unstructured":"Soliman, H., Mediavilla-Varela, M. & Antonia, S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J. 16, 354\u2013359 (2010).","journal-title":"Cancer J."},{"key":"203_CR83","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0959-8049(16)30315-X","volume":"51","author":"Y Zakharia","year":"2015","unstructured":"Zakharia, Y. et al. Results of phase 1b trial of the indoleamine 2,3-dioxygenase (IDO) pathway inhibitor indoximod plus ipilimumab for the treatment of unresectable stage III or IV melanoma. Eur. J. Cancer 51, S108 (2015).","journal-title":"Eur. J. Cancer"},{"key":"203_CR84","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","volume":"8","author":"EW Yue","year":"2017","unstructured":"Yue, E. W. et al. INCB24360 (epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology. ACS Med. Chem. Lett. 8, 486\u2013491 (2017).","journal-title":"ACS Med. Chem. Lett."},{"key":"203_CR85","first-page":"307","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard, A. IDO takes a blow. Nat. Rev. Drug Discov. 17, 307 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"203_CR86","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374\u2013388 (2016).","journal-title":"Immunity"},{"key":"203_CR87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"MD Buck","year":"2016","unstructured":"Buck, M. D. et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166, 63\u201376 (2016).","journal-title":"Cell"},{"key":"203_CR88","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N.\u00a0Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"203_CR89","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","volume":"118","author":"C Hartmann","year":"2009","unstructured":"Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469\u2013474 (2009).","journal-title":"Acta Neuropathol."},{"key":"203_CR90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.24379","volume":"125","author":"MR Kang","year":"2009","unstructured":"Kang, M. R. et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int.\u00a0J. Cancer 125, 353\u2013355 (2009).","journal-title":"Int. J. Cancer"},{"key":"203_CR91","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/j.1349-7006.2009.01270.x","volume":"100","author":"Y Sonoda","year":"2009","unstructured":"Sonoda, Y. et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 100, 1996\u20131998 (2009).","journal-title":"Cancer Sci."},{"key":"203_CR92","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","volume":"31","author":"BC Medeiros","year":"2016","unstructured":"Medeiros, B. C. et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 31, 272 (2016).","journal-title":"Leukemia"},{"key":"203_CR93","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12700","volume":"7","author":"M Carbonneau","year":"2016","unstructured":"Carbonneau, M. et al. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat. Commun. 7, 12700 (2016).","journal-title":"Nat. Commun."},{"key":"203_CR94","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller, J. et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med. Chem. Lett. 9, 300\u2013305 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"203_CR95","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V124.21.3735.3735","volume":"124","author":"C Quivoron","year":"2014","unstructured":"Quivoron, C. et al. AG-221, an oral, selective, first-in-class, potent IDH2-R140Q mutant inhibitor, induces differentiation in a xenotransplant model. Blood 124, 3735 (2014).","journal-title":"Blood"},{"key":"203_CR96","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1200\/JCO.2018.36.15_suppl.7042","volume":"36","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). J. Clin. Oncol. 36, 7042 (2018).","journal-title":"J. Clin. Oncol."},{"key":"203_CR97","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386\u20132398 (2018).","journal-title":"N. Engl. J. Med."},{"key":"203_CR98","first-page":"1990","volume":"7","author":"P Agarwal","year":"2017","unstructured":"Agarwal, P. et al. Elucidating immunometabolic targets in glioblastoma. Am. J. Cancer Res. 7, 1990\u20131995 (2017).","journal-title":"Am. J. Cancer Res."},{"key":"203_CR99","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","volume":"24","author":"L Bunse","year":"2018","unstructured":"Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192\u20131203 (2018).","journal-title":"Nat. Med."},{"key":"203_CR100","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425\u20131437 (2017).","journal-title":"J. Clin. Invest."},{"key":"203_CR101","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1101\/gad.294991.116","volume":"31","author":"NM Amankulor","year":"2017","unstructured":"Amankulor, N. M. et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 31, 774\u2013786 (2017).","journal-title":"Genes Dev."},{"key":"203_CR102","doi-asserted-by":"crossref","first-page":"14274","DOI":"10.1074\/jbc.M115.685792","volume":"291","author":"T Cordes","year":"2016","unstructured":"Cordes, T. et al. Immunoresponsive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels. J. Biol. Chem. 291, 14274\u201314284 (2016).","journal-title":"J. Biol. Chem."},{"key":"203_CR103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cmet.2016.06.004","volume":"24","author":"V Lampropoulou","year":"2016","unstructured":"Lampropoulou, V. et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell\u00a0Metab. 24, 158\u2013166 (2016).","journal-title":"Cell Metab."},{"key":"203_CR104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature25986","volume":"556","author":"EL Mills","year":"2018","unstructured":"Mills, E. L. et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556, 113 (2018).","journal-title":"Nature"},{"key":"203_CR105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41586-018-0052-z","volume":"556","author":"M Bambouskova","year":"2018","unstructured":"Bambouskova, M. et al. Electrophilic properties of itaconate and derivatives regulate the I\u03baB\u03b6\u2013ATF3 inflammatory axis. Nature 556, 501\u2013504 (2018).","journal-title":"Nature"},{"key":"203_CR106","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","volume":"40","author":"J Xue","year":"2014","unstructured":"Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274\u2013288 (2014).","journal-title":"Immunity"},{"key":"203_CR107","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1172\/JCI99169","volume":"128","author":"JM Weiss","year":"2018","unstructured":"Weiss, J. M. et al. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. J. Clin. Invest. 128, 3794\u20133805 (2018).","journal-title":"J. Clin. Invest."},{"key":"203_CR108","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/01.RES.43.3.390","volume":"43","author":"WL Miller","year":"1978","unstructured":"Miller, W. L., Thomas, R. A., Berne, R. M. & Rubio, R. Adenosine production in the ischemic kidney. Circ. Res. 43, 390\u2013397 (1978).","journal-title":"Circ. Res."},{"key":"203_CR109","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D., Young, A., Teng, M. W. L. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17, 709\u2013724 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"203_CR110","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli, L., Blandizzi, C., Pacher, P. & Hask\u00f3, G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842\u2013857 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"203_CR111","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3892\/ol.2016.5189","volume":"12","author":"X-Y Cai","year":"2016","unstructured":"Cai, X.-Y. et al. High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncol. Lett. 12, 4080\u20134086 (2016).","journal-title":"Oncol. Lett."},{"key":"203_CR112","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3748\/wjg.v19.i12.1912","volume":"19","author":"X-X Lu","year":"2013","unstructured":"Lu, X.-X. et al. Expression and clinical significance of CD73 and hypoxia-inducible factor-1\u03b1 in gastric carcinoma. World J. Gastroenterol. 19, 1912\u20131918 (2013).","journal-title":"World J. Gastroenterol."},{"key":"203_CR113","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","volume":"75","author":"M Turcotte","year":"2015","unstructured":"Turcotte, M. et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 75, 4494 (2015).","journal-title":"Cancer Res."},{"key":"203_CR114","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.18632\/oncotarget.14434","volume":"8","author":"Y Inoue","year":"2017","unstructured":"Inoue, Y. et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget 8, 8738\u20138751 (2017).","journal-title":"Oncotarget"},{"key":"203_CR115","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332\u20131341 (2017).","journal-title":"Nat. Immunol."},{"key":"203_CR116","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2010.05.007","volume":"139","author":"X Sun","year":"2010","unstructured":"Sun, X. et al. CD39\/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139, 1030\u20131040 (2010).","journal-title":"Gastroenterology"},{"key":"203_CR117","volume":"7","author":"RF Zanin","year":"2012","unstructured":"Zanin, R. F. et al. Differential macrophage activation alters the expression profile of NTPDase and Ecto-5\u2032nucleotidase. PLOS ONE 7, e31205 (2012).","journal-title":"PLOS ONE"},{"key":"203_CR118","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1096\/fj.11-190934","volume":"26","author":"B Cs\u00f3ka","year":"2012","unstructured":"Cs\u00f3ka, B. et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 26, 376\u2013386 (2012).","journal-title":"FASEB J."},{"key":"203_CR119","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","volume":"90","author":"S Huang","year":"1997","unstructured":"Huang, S., Apasov, S., Koshiba, M. & Sitkovsky, M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T cell activation and expansion. Blood 90, 1600\u20131610 (1997).","journal-title":"Blood"},{"key":"203_CR120","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard, B., Pommey, S., Smyth, M. J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19, 5626\u20135635 (2013).","journal-title":"Clin. Cancer Res."},{"key":"203_CR121","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","volume":"3","author":"A Ohta","year":"2012","unstructured":"Ohta, A. et al. The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Frontiers Immunol. 3, 190 (2012).","journal-title":"Frontiers Immunol."},{"key":"203_CR122","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1172\/JCI63170","volume":"122","author":"L Li","year":"2012","unstructured":"Li, L. et al. Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury. J. Clin. Invest. 122, 3931\u20133942 (2012).","journal-title":"J. Clin. Invest."},{"key":"203_CR123","doi-asserted-by":"crossref","first-page":"27478","DOI":"10.18632\/oncotarget.4393","volume":"6","author":"C Sorrentino","year":"2015","unstructured":"Sorrentino, C., Miele, L., Porta, A., Pinto, A. & Morello, S. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget 6, 27478\u201327489 (2015).","journal-title":"Oncotarget"},{"key":"203_CR124","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2353\/ajpath.2007.070190","volume":"171","author":"SW Jackson","year":"2007","unstructured":"Jackson, S. W. et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39\/Entpd1-null mice. Am. J. Pathol. 171, 1395\u20131404 (2007).","journal-title":"Am. J. Pathol."},{"key":"203_CR125","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1523-1747.2002.00111.x","volume":"119","author":"S Merighi","year":"2002","unstructured":"Merighi, S. et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J. Invest. Dermatol. 119, 923\u2013933 (2002).","journal-title":"J. Invest. Dermatol."},{"key":"203_CR126","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1349-7006.2010.01733.x","volume":"101","author":"X Zhi","year":"2010","unstructured":"Zhi, X. et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 101, 2561\u20132569 (2010).","journal-title":"Cancer Sci."},{"key":"203_CR127","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4161\/cbt.6.3.3762","volume":"6","author":"P Zhou","year":"2007","unstructured":"Zhou, P. et al. Overexpression of Ecto-5\u2032-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix. Cancer Biol. Ther. 6, 426\u2013431 (2007).","journal-title":"Cancer Biol. Ther."},{"key":"203_CR128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00432-007-0292-z","volume":"134","author":"L Wang","year":"2008","unstructured":"Wang, L. et al. Ecto-5\u2032-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J. Cancer Res. Clin. Oncol. 134, 365\u2013372 (2008).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"203_CR129","first-page":"172","volume":"4","author":"R Iannone","year":"2014","unstructured":"Iannone, R., Miele, L., Maiolino, P., Pinto, A. & Morello, S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4, 172\u2013181 (2014).","journal-title":"Am. J. Cancer Res."},{"key":"203_CR130","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis, P. A. et al. Adenosine receptor 2A blockade increases the efficacy of anti\u2013PD-1 through enhanced antitumor T cell responses. Cancer Immunol. Res. 3, 506 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"203_CR131","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-14-0957","volume":"74","author":"D Mittal","year":"2014","unstructured":"Mittal, D. et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74, 3652 (2014).","journal-title":"Cancer Res."},{"key":"203_CR132","unstructured":"Corvus Pharmaceuticals. Corvus Pharmaceuticals announces interim results from ongoing phase 1\/1b study demonstrating safety and clinical activity of lead checkpoint inhibitor CPI-444 in patients with advanced cancers. GlobeNewsWire https:\/\/globenewswire.com\/news-release\/2017\/04\/04\/954192\/0\/en\/Corvus-Pharmaceuticals-Announces-Interim-Results-from-Ongoing-Phase-1-1b-Study-Demonstrating-Safety-and-Clinical-Activity-of-Lead-Checkpoint-Inhibitor-CPI-444-in-Patients-with-Adva.html (2017)."},{"key":"203_CR133","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2017.12.008","volume":"185","author":"GJ Mart\u00ednez-Col\u00f3n","year":"2018","unstructured":"Mart\u00ednez-Col\u00f3n, G. J. & Moore, B. B. Prostaglandin E2 as a regulator of immunity to pathogens. Pharmacol. Ther. 185, 135\u2013146 (2018).","journal-title":"Pharmacol. Ther."},{"key":"203_CR134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.08.001","volume":"193","author":"RS Peebles Jr","year":"2018","unstructured":"Peebles, R. S. Jr Prostaglandins in asthma and allergic diseases. Pharmacol. Ther. 193, 1\u201319 (2018).","journal-title":"Pharmacol. Ther."},{"key":"203_CR135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrendo.2010.194","volume":"7","author":"T Furuyashiki","year":"2011","unstructured":"Furuyashiki, T. & Narumiya, S. Stress responses: the contribution of prostaglandin E(2) and its receptors. Nat. Rev. Endocrinol. 7, 163\u2013175 (2011).","journal-title":"Nat. Rev. Endocrinol."},{"key":"203_CR136","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257\u20131270 (2015).","journal-title":"Cell"},{"key":"203_CR137","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","volume":"65","author":"S Sharma","year":"2005","unstructured":"Sharma, S. et al. Tumor cyclooxygenase-2\/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65, 5211\u20135220 (2005).","journal-title":"Cancer Res."},{"key":"203_CR138","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","volume":"175","author":"F Baratelli","year":"2005","unstructured":"Baratelli, F. et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 175, 1483\u20131490 (2005).","journal-title":"J. Immunol."},{"key":"203_CR139","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4049\/jimmunol.177.1.246","volume":"177","author":"M Mahic","year":"2006","unstructured":"Mahic, M., Yaqub, S., Johansson, C. C., Task\u00e9n, K. & Aandahl, E. M. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 177, 246\u2013254 (2006).","journal-title":"J. Immunol."},{"key":"203_CR140","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.4049\/jimmunol.150.12.5321","volume":"150","author":"FG Snijdewint","year":"1993","unstructured":"Snijdewint, F. G., Kalinski, P., Wierenga, E. A., Bos, J. D. & Kapsenberg, M. L. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150, 5321\u20135329 (1993).","journal-title":"J. Immunol."},{"key":"203_CR141","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1002\/eji.1830271254","volume":"27","author":"CE Demeure","year":"1997","unstructured":"Demeure, C. E., Yang, L. P., Desjardins, C., Raynauld, P. & Delespesse, G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur. J. Immunol. 27, 3526\u20133531 (1997).","journal-title":"Eur. J. Immunol."},{"key":"203_CR142","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.1424355112","volume":"112","author":"K Larsson","year":"2015","unstructured":"Larsson, K. et al. COX\/mPGES-1\/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc. Natl Acad. Sci. USA 112, 8070\u20138075 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"203_CR143","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/08820139.2012.695417","volume":"41","author":"N Obermajer","year":"2012","unstructured":"Obermajer, N. et al. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol. Invest. 41, 635\u2013657 (2012).","journal-title":"Immunol. Invest."},{"key":"203_CR144","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037 (2018).","journal-title":"Cell"},{"key":"203_CR145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.3831","volume":"21","author":"JH Chen","year":"2015","unstructured":"Chen, J. H. et al. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat. Med. 21, 327\u2013334 (2015).","journal-title":"Nat. Med."},{"key":"203_CR146","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrclinonc.2012.137","volume":"9","author":"WK Chia","year":"2012","unstructured":"Chia, W. K., Ali, R. & Toh, H. C. Aspirin as adjuvant therapy for colorectal cancer \u2014 reinterpreting paradigms. Nat. Rev. Clin. Oncol. 9, 561\u2013570 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"203_CR147","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","volume":"16","author":"DA Drew","year":"2016","unstructured":"Drew, D. A., Cao, Y. & Chan, A. T. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat. Rev. Cancer 16, 173\u2013186 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"203_CR148","volume":"5","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. OncoImmunology 5, e1074374 (2016).","journal-title":"OncoImmunology"},{"key":"203_CR149","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/0008-5472.CAN-05-3702","volume":"66","author":"SD Chell","year":"2006","unstructured":"Chell, S. D. et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res. 66, 3106\u20133113 (2006).","journal-title":"Cancer Res."},{"key":"203_CR150","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1073\/pnas.0510562103","volume":"103","author":"FG Buchanan","year":"2006","unstructured":"Buchanan, F. G. et al. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl Acad. Sci. USA 103, 1492\u20131497 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"203_CR151","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s12013-014-9951-2","volume":"70","author":"S Xu","year":"2014","unstructured":"Xu, S. et al. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer. Cell Biochem. Biophys. 70, 521\u2013527 (2014).","journal-title":"Cell Biochem. Biophys."},{"key":"203_CR152","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/bjc.2017.393","volume":"118","author":"E Kashiwagi","year":"2018","unstructured":"Kashiwagi, E. et al. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. Br. J. Cancer 118, 213\u2013223 (2018).","journal-title":"Br. J. Cancer"},{"key":"203_CR153","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/cas.12475","volume":"105","author":"M Majumder","year":"2014","unstructured":"Majumder, M., Xin, X., Liu, L., Girish, G. V. & Lala, P. K. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci. 105, 1142\u20131151 (2014).","journal-title":"Cancer Sci."},{"key":"203_CR154","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/stem.2426","volume":"34","author":"M Majumder","year":"2016","unstructured":"Majumder, M. et al. COX-2 induces breast cancer stem cells via EP4\/PI3K\/AKT\/NOTCH\/WNT axis. Stem Cells 34, 2290\u20132305 (2016).","journal-title":"Stem Cells"},{"key":"203_CR155","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1111\/bph.13331","volume":"172","author":"G O\u2019Callaghan","year":"2015","unstructured":"O\u2019Callaghan, G. & Houston, A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br. J. Pharmacol. 172, 5239\u20135250 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"203_CR156","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drudis.2016.08.003","volume":"22","author":"T Markovic","year":"2017","unstructured":"Markovic, T., Jakopin, \u017d., Dolenc, M. S. & Mlinaric-Ra\u0161can, I. Structural features of subtype-selective EP receptor modulators. Drug Discov. Today 22, 57\u201371 (2017).","journal-title":"Drug Discov. Today"},{"key":"203_CR157","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153\u2013161 (2013).","journal-title":"Cell Metab."},{"key":"203_CR158","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1158\/0008-5472.CAN-13-0530","volume":"73","author":"L Bochet","year":"2013","unstructured":"Bochet, L. et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73, 5657\u20135668 (2013).","journal-title":"Cancer Res."},{"key":"203_CR159","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/0008-5472.CAN-12-0294","volume":"72","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res. 72, 5198\u20135208 (2012).","journal-title":"Cancer Res."},{"key":"203_CR160","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880\u2013886 (2010).","journal-title":"Nat. Med."},{"key":"203_CR161","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"203_CR162","volume":"6","author":"AA Al-Khami","year":"2017","unstructured":"Al-Khami, A. A. et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology 6, e1344804 (2017).","journal-title":"Oncoimmunology"},{"key":"203_CR163","volume":"8","author":"Z Niu","year":"2017","unstructured":"Niu, Z. et al. Caspase-1 cleaves PPAR\u03b3 for potentiating the pro-tumor action of TAMs. Nat. Commun. 8, 766 (2017).","journal-title":"Nat. Commun."},{"key":"203_CR164","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"203_CR165","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1172\/JCI69571","volume":"124","author":"G McDonald","year":"2014","unstructured":"McDonald, G. et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J.\u00a0Clin. Invest. 124, 712\u2013724 (2014).","journal-title":"J. Clin. Invest."},{"key":"203_CR166","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4049\/jimmunol.1601318","volume":"198","author":"IA Bettencourt","year":"2017","unstructured":"Bettencourt, I. A. & Powell, J. D. Targeting metabolism as a novel therapeutic approach to autoimmunity, inflammation, and transplantation. J. Immunol. 198, 999 (2017).","journal-title":"J. Immunol."},{"key":"203_CR167","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/emboj.2009.6","volume":"28","author":"T Zech","year":"2009","unstructured":"Zech, T. et al. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 28, 466 (2009).","journal-title":"EMBO J."},{"key":"203_CR168","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/09687688.2010.495353","volume":"27","author":"DM Owen","year":"2010","unstructured":"Owen, D. M. et al. High plasma membrane lipid order imaged at the immunological synapse periphery in live T cells. Mol. Membr. Biol. 27, 178\u2013189 (2010).","journal-title":"Mol. Membr. Biol."},{"key":"203_CR169","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang, W. et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature 531, 651 (2016).","journal-title":"Nature"},{"key":"203_CR170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32, 377\u2013391 (2017).","journal-title":"Cancer Cell"},{"key":"203_CR171","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-18-0095","volume":"6","author":"PS Chowdhury","year":"2018","unstructured":"Chowdhury, P. S., Chamoto, K., Kumar, A. & Honjo, T. PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy. Cancer Immunol. Res. 6, 1375\u20131387 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"203_CR172","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.immuni.2015.09.007","volume":"43","author":"A Haghikia","year":"2015","unstructured":"Haghikia, A. et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43, 817\u2013829 (2015).","journal-title":"Immunity"},{"key":"203_CR173","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mi.2014.44","volume":"8","author":"J Park","year":"2014","unstructured":"Park, J. et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR\u2013S6K pathway. Mucosal Immunol. 8, 80 (2014).","journal-title":"Mucosal Immunol."},{"key":"203_CR174","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.cell.2015.11.045","volume":"163","author":"AG York","year":"2015","unstructured":"York, A. G. et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell 163, 1716\u20131729 (2015).","journal-title":"Cell"},{"key":"203_CR175","volume":"6","author":"D Sag","year":"2015","unstructured":"Sag, D., Cekic, C., Wu, R., Linden, J. & Hedrick, C. C. The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nat. Commun. 6, 6354 (2015).","journal-title":"Nat. Commun."},{"key":"203_CR176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005783","volume":"12","author":"Y Kannan","year":"2016","unstructured":"Kannan, Y. et al. TPL-2 regulates macrophage lipid metabolism and M2 differentiation to control TH2-mediated immunopathology. PLOS Pathog. 12, e1005783 (2016).","journal-title":"PLOS Pathog."},{"key":"203_CR177","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ni.2956","volume":"15","author":"SC Huang","year":"2014","unstructured":"Huang, S. C. et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat. Immunol. 15, 846\u2013855 (2014).","journal-title":"Nat. Immunol."},{"key":"203_CR178","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"203_CR179","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2018.04.007","volume":"41","author":"VP Mourits","year":"2018","unstructured":"Mourits, V. P., Wijkmans, J. C., Joosten, L. A. & Netea, M. G. Trained immunity as a novel therapeutic strategy. Curr. Opin. Pharmacol. 41, 52\u201358 (2018).","journal-title":"Curr. Opin. Pharmacol."},{"key":"203_CR180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004485","volume":"10","author":"K Buffen","year":"2014","unstructured":"Buffen, K. et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLOS Pathog. 10, e1004485 (2014).","journal-title":"PLOS Pathog."},{"key":"203_CR181","doi-asserted-by":"crossref","first-page":"1250684","DOI":"10.1126\/science.1250684","volume":"345","author":"SC Cheng","year":"2014","unstructured":"Cheng, S. C. et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).","journal-title":"Science"},{"key":"203_CR182","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","volume":"24","author":"RJ Arts","year":"2016","unstructured":"Arts, R. J. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807\u2013819 (2016).","journal-title":"Cell Metab."},{"key":"203_CR183","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1074\/jbc.M113.522037","volume":"289","author":"AJ Freemerman","year":"2014","unstructured":"Freemerman, A. J. et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J. Biol. Chem. 289, 7884\u20137896 (2014).","journal-title":"J. Biol. Chem."},{"key":"203_CR184","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis, N. et al. PD-1 alters T cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6, 6692 (2015).","journal-title":"Nat. Commun."},{"key":"203_CR185","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-15-1538","volume":"76","author":"S Lim","year":"2016","unstructured":"Lim, S. et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1. Cancer Res. 76, 2231\u20132242 (2016).","journal-title":"Cancer Res."},{"key":"203_CR186","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543\u20139553 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"203_CR187","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","volume":"193","author":"RL Ferris","year":"2014","unstructured":"Ferris, R. L., Lu, B. & Kane, L. P. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J.\u00a0Immunol. 193, 1525\u20131530 (2014).","journal-title":"J. Immunol."},{"key":"203_CR188","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee, J. et al. Phosphotyrosine-dependent coupling of Tim-3 to T cell receptor signaling pathways. Mol. Cell. Biol. 31, 3963\u20133974 (2011).","journal-title":"Mol. Cell. Biol."},{"issue":"Suppl","key":"203_CR189","first-page":"150.1","volume":"198","author":"DM Previte","year":"2017","unstructured":"Previte, D. M. et al. Lymphocyte activation gene-3 regulates mitochondrial biogenesis and metabolism of naive CD4+ T cells. J. Immunol. 198 (Suppl), 150.1 (2017).","journal-title":"Immunol."},{"key":"203_CR190","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.4049\/jimmunol.180.7.4476","volume":"180","author":"SR Jacobs","year":"2008","unstructured":"Jacobs, S. R. et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180, 4476\u20134486 (2008).","journal-title":"J. Immunol."},{"key":"203_CR191","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cell.2017.08.018","volume":"171","author":"GRI Klein","year":"2017","unstructured":"Klein, G. R. I. et al. Mitochondrial priming by CD28. Cell 171, 385\u2013397 (2017).","journal-title":"Cell"},{"key":"203_CR192","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/cmi.2016.02","volume":"14","author":"BK Choi","year":"2017","unstructured":"Choi, B. K. et al. 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation. Cell. Mol. Immunol. 14, 748\u2013757 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"203_CR193","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4049\/jimmunol.1501217","volume":"196","author":"N Tsurutani","year":"2016","unstructured":"Tsurutani, N. et al. Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis. J. Immunol. 196, 124\u2013134 (2016).","journal-title":"J. Immunol."},{"key":"203_CR194","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1158\/2326-6066.CIR-17-0632","volume":"6","author":"SS Sabharwal","year":"2018","unstructured":"Sabharwal, S. S. et al. GITR agonism enhances cellular metabolism to support CD8+ T cell proliferation and effector cytokine production in a mouse tumor model. Cancer Immunol. Res. 6, 1199\u20131211 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"203_CR195","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.immuni.2016.08.017","volume":"45","author":"H Zeng","year":"2016","unstructured":"Zeng, H. et al. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation. Immunity 45, 540\u2013554 (2016).","journal-title":"Immunity"},{"key":"203_CR196","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.molimm.2014.01.008","volume":"59","author":"M Gigoux","year":"2014","unstructured":"Gigoux, M. et al. Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation. Mol. Immunol. 59, 46\u201354 (2014).","journal-title":"Mol. Immunol."},{"key":"203_CR197","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.celrep.2018.01.040","volume":"22","author":"AV Menk","year":"2018","unstructured":"Menk, A. V. et al. Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep. 22, 1509\u20131521 (2018).","journal-title":"Cell Rep."},{"key":"203_CR198","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mito.2017.10.006","volume":"41","author":"G Desdin-Mico","year":"2018","unstructured":"Desdin-Mico, G., Soto-Heredero, G. & Mittelbrunn, M. Mitochondrial activity in T cells. Mitochondrion 41, 51\u201357 (2018).","journal-title":"Mitochondrion"},{"key":"203_CR199","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","volume":"38","author":"LA Sena","year":"2013","unstructured":"Sena, L. A. et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38, 225\u2013236 (2013).","journal-title":"Immunity"},{"key":"203_CR200","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ni.2687","volume":"14","author":"PM Gubser","year":"2013","unstructured":"Gubser, P. M. et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat. Immunol. 14, 1064\u20131072 (2013).","journal-title":"Nat. Immunol."},{"key":"203_CR201","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2018.02.012","volume":"48","author":"GR Bantug","year":"2018","unstructured":"Bantug, G. R. et al. Mitochondria-endoplasmic reticulum contact sites function as immunometabolic hubs that orchestrate the rapid recall response of memory CD8+ T cells. Immunity 48, 542\u2013555 (2018).","journal-title":"Immunity"},{"key":"203_CR202","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20171068","volume":"215","author":"AV Menk","year":"2018","unstructured":"Menk, A. V. et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp. Med. 215, 1091\u20131100 (2018).","journal-title":"J. Exp. Med."},{"key":"203_CR203","doi-asserted-by":"crossref","first-page":"93411","DOI":"10.1172\/jci.insight.93411","volume":"2","author":"PJ Siska","year":"2017","unstructured":"Siska, P. J. et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight 2, 93411 (2017).","journal-title":"JCI Insight"},{"key":"203_CR204","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/ni.3025","volume":"15","author":"X Xu","year":"2014","unstructured":"Xu, X. et al. Autophagy is essential for effector CD8+ T cell survival and memory formation. Nat. Immunol. 15, 1152\u20131161 (2014).","journal-title":"Nat. Immunol."},{"key":"203_CR205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08097","volume":"460","author":"EL Pearce","year":"2009","unstructured":"Pearce, E. L. et al. Enhancing CD8 T cell memory by modulating fatty acid metabolism. Nature 460, 103\u2013107 (2009).","journal-title":"Nature"},{"key":"203_CR206","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23993-0","volume":"8","author":"D Murera","year":"2018","unstructured":"Murera, D. et al. CD4 T cell autophagy is integral to memory maintenance. Sci. Rep. 8, 5951 (2018).","journal-title":"Sci. Rep."},{"key":"203_CR207","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.1201940","volume":"333","author":"DR Green","year":"2011","unstructured":"Green, D. R., Galluzzi, L. & Kroemer, G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 333, 1109\u20131112 (2011).","journal-title":"Science"},{"key":"203_CR208","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2015.07.012","volume":"43","author":"TE O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan, T. E., Johnson, L. R., Kang, H. H. & Sun, J. C. BNIP3- and BNIP3L-mediated mitophagy promotes the generation of natural killer cell memory. Immunity 43, 331\u2013342 (2015).","journal-title":"Immunity"},{"key":"203_CR209","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs, C. S. & Rosenberg, S. A. Exploiting the curative potential of adoptive T cell therapy for cancer. Immunol. Rev. 257, 56\u201371 (2014).","journal-title":"Immunol. Rev."},{"key":"203_CR210","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","volume":"17","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff, C. A. et al. Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343\u20135352 (2011).","journal-title":"Clin. Cancer Res."},{"key":"203_CR211","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc.\u00a0Natl Acad. Sci. USA 101, 1969\u20131974 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"203_CR212","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","volume":"36","author":"GJ Windt van der","year":"2012","unstructured":"van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68\u201378 (2012).","journal-title":"Immunity"},{"key":"203_CR213","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","volume":"460","author":"K Araki","year":"2009","unstructured":"Araki, K. et al. mTOR regulates memory CD8 T cell differentiation. Nature 460, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"203_CR214","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/0008-5472.CAN-14-2277","volume":"75","author":"JG Crompton","year":"2015","unstructured":"Crompton, J. G. et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 75, 296\u2013305 (2015).","journal-title":"Cancer Res."},{"key":"203_CR215","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.celrep.2015.12.095","volume":"14","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a foxo1-dependent manner. Cell Rep. 14, 1206\u20131217 (2016).","journal-title":"Cell Rep."},{"key":"203_CR216","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","volume":"537","author":"R Eil","year":"2016","unstructured":"Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539\u2013543 (2016).","journal-title":"Nature"},{"key":"203_CR217","doi-asserted-by":"crossref","first-page":"95103","DOI":"10.1172\/jci.insight.95103","volume":"2","author":"CA Klebanoff","year":"2017","unstructured":"Klebanoff, C. A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2, 95103 (2017).","journal-title":"JCI Insight"},{"key":"203_CR218","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"W Zheng","year":"2018","unstructured":"Zheng, W. et al. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32, 1157\u20131167 (2018).","journal-title":"Leukemia"},{"key":"203_CR219","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769\u2013777 (2002).","journal-title":"Immunity"},{"key":"203_CR220","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1172\/JCI69589","volume":"123","author":"M Sukumar","year":"2013","unstructured":"Sukumar, M. et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 123, 4479\u20134488 (2013).","journal-title":"J. Clin. Invest."},{"key":"203_CR221","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 712 (2016).","journal-title":"Immunity"},{"key":"203_CR222","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.intimp.2018.07.031","volume":"63","author":"L Lima Thomaz de","year":"2018","unstructured":"de Lima Thomaz, L. et al. The impact of metabolic reprogramming on dendritic cell function. Int. Immunopharmacol. 63, 84\u201393 (2018).","journal-title":"Int. Immunopharmacol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0203-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0203-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0203-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:58:47Z","timestamp":1694714327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0203-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":222,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0203-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"26 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.R. is a member of the scientific advisory board of Immatics and NexImmune and has received speaker honoraria from AstraZeneca, Bristol-Myers Squibb and Roche and research funding from Roche in the form of a Pharma Research and Early Development (pRED) grant. S.-M.F. has received funding from Bayer and Merck. P.-C.H. has received research funding from Idorsia, Novartis and Roche (pRED grant) and speaker honoraria from Chugai and Pfizer and is a member of the scientific advisory board of Elixiron Immunotherapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}